Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XLSWN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SC-006
|
|||||
| Synonyms |
SC-006
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-RNF43 antibody
|
Antibody Info | ||||
| Antigen Name |
E3 ubiquitin-protein ligase RNF43 (RNF43)
|
Antigen Info | ||||
| Payload Name |
SG3312 (SC-DR003)
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Colorectal cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | stable disease (SD) |
34%
|
|||
| Patients Enrolled |
Eligible participants must have advanced metastatic CRC refractory to ≥2 prior systemic therapies, ECOG 0-1, and adequate organ function. Key exclusions include prior PBD/IND-based drug exposure, autoimmune/immunodeficiency disorders, IBD history, or recent immunosuppressant use within 14 days prior to treatment. Combination therapy excludes patients with immune-mediated pneumonitis or transplant history.
Click to Show/Hide
|
||||
| Administration Dosage |
As of April 2019, 29 patients were enrolled (n=20 in part A and n=9 in part B). All patients experienced at least one treatment-emergent adverse event (TEAE). Two patients (7%) had dose-limiting toxicities of grade 4 thrombocytopenia. All 29 patients discontinued from the study, with study drug being discontinued for 76% of patients due to progressive disease. One death occurred in part A due to gastrointestinal hemorrhage with possible relation to SC-006. Serious TEAEs occurred in 8 patients (28%); these included thrombocytopenia and malignant neoplasm progression in 2 patients (7%) each.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | ||||
| Primary Endpoint |
Safety assessment focuses on dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.03 during the initial 21-day treatment cycle.
|
||||
| Other Endpoint |
Efficacy endpoints include overall survival (OS) and progression-free survival (PFS) over approximately 2 years, along with pharmacokinetic parameters (Tmax, AUC, T1/2, Cmax, Ctrough) of SC-006 evaluated over 1 year. Tumor response is measured via objective response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR) using RECIST v1.1 criteria.
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | progressive disease (PD) |
62%
|
|||
| Patients Enrolled |
Eligible participants must have advanced metastatic CRC refractory to ≥2 prior systemic therapies, ECOG 0-1, and adequate organ function. Key exclusions include prior PBD/IND-based drug exposure, autoimmune/immunodeficiency disorders, IBD history, or recent immunosuppressant use within 14 days prior to treatment. Combination therapy excludes patients with immune-mediated pneumonitis or transplant history.
Click to Show/Hide
|
||||
| Administration Dosage |
As of April 2019, 29 patients were enrolled (n=20 in part A and n=9 in part B). All patients experienced at least one treatment-emergent adverse event (TEAE). Two patients (7%) had dose-limiting toxicities of grade 4 thrombocytopenia. All 29 patients discontinued from the study, with study drug being discontinued for 76% of patients due to progressive disease. One death occurred in part A due to gastrointestinal hemorrhage with possible relation to SC-006. Serious TEAEs occurred in 8 patients (28%); these included thrombocytopenia and malignant neoplasm progression in 2 patients (7%) each.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | ||||
| Primary Endpoint |
Safety assessment focuses on dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.03 during the initial 21-day treatment cycle.
|
||||
| Other Endpoint |
Efficacy endpoints include overall survival (OS) and progression-free survival (PFS) over approximately 2 years, along with pharmacokinetic parameters (Tmax, AUC, T1/2, Cmax, Ctrough) of SC-006 evaluated over 1 year. Tumor response is measured via objective response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR) using RECIST v1.1 criteria.
Click to Show/Hide
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0%
|
|||
| Patients Enrolled |
Patients with advanced metastatic or unresectable colorectal cancer.
|
||||
| Administration Dosage |
SC-006-monotherapy, 2 to 12 ug/kg IV every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | Phase 1 | ||
| Clinical Description | An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer. | ||||
References